Kang Won-Ho, Nguyen Hien Van, Park Chulhun, Choi Youn-Woong, Lee Beom-Jin
College of Pharmacy, Ajou University, Suwon 16499, Republic of Korea; Korea United Pharm Inc., Seoul 135010, Republic of Korea.
College of Pharmacy, Ajou University, Suwon 16499, Republic of Korea.
Eur J Pharm Sci. 2017 May 1;102:85-93. doi: 10.1016/j.ejps.2017.02.039. Epub 2017 Mar 2.
This study was designed to develop a once-daily controlled-release matrix tablet of aceclofenac 200mg (AFC-CR) with dual release characteristics and to investigate the role of an alkalizer in enhancing drug solubility and reducing the occurrence of gastroduodenal mucosal lesions. Two formulation approaches were employed, namely a monolithic matrix tablet and a bilayered tablet. In vitro dissolution studies of AFC-CR tablets were carried out in simulated intestinal fluid (pH6.8 buffer). The in vivo pharmacokinetic studies and drug safety of the immediate-release reference tablet Airtal® 100mg (Daewoong Co., Korea) and the optimized AFC-CR tablet were compared in beagle dogs under fasted condition. The optimally selected AFC-CR formulation displayed the desired dual release characteristics in simulated intestinal fluid with satisfactory micromeritic properties. The swelling action of the optimal matrix tablet, which was visualized by near-infrared (NIR) chemical imaging, occurred rapidly following hydration. Incorporation of sodium carbonate (NaCO) was found to enhance the release rate of the AFC-CR bilayered tablets at early stages and increase the microenvironmental pH (pH). A pharmacokinetic study in beagle dogs indicated a higher drug plasma concentration and a sustained-release pattern for the AFC-CR tablet compared to the Airtal® tablet. AFC-CR was also superior to Airtal® in terms of in vivo drug safety, since no beagle dog receiving AFC-CR experienced gastrointestinal bleeding. The significant enhancement of drug safety was attributed to the size reduction and the increase of pH of drug particles by means of incorporation of the alkalizer. These findings provide a scientific rationale for developing a novel controlled-release matrix tablet with enhanced patient compliance and better pain control.
本研究旨在开发一种具有双重释放特性的每日一次的200mg醋氯芬酸控释骨架片(AFC-CR),并研究一种碱化剂在提高药物溶解度和减少胃十二指肠粘膜损伤发生方面的作用。采用了两种制剂方法,即整体骨架片和双层片。在模拟肠液(pH6.8缓冲液)中对AFC-CR片进行了体外溶出度研究。在禁食条件下,在比格犬中比较了速释参比片Airtal® 100mg(韩国大宇公司)和优化后的AFC-CR片的体内药代动力学研究和药物安全性。最佳选择的AFC-CR制剂在模拟肠液中表现出所需的双重释放特性,且具有令人满意的粉体学性质。通过近红外(NIR)化学成像观察到的最佳骨架片的溶胀作用在水化后迅速发生。发现加入碳酸钠(NaCO)可提高AFC-CR双层片早期的释放速率,并提高微环境pH值(pH)。比格犬的药代动力学研究表明,与Airtal®片相比,AFC-CR片具有更高的血浆药物浓度和缓释模式。在体内药物安全性方面,AFC-CR也优于Airtal®,因为接受AFC-CR的比格犬没有出现胃肠道出血。药物安全性的显著提高归因于通过加入碱化剂使药物颗粒尺寸减小和pH值增加。这些发现为开发一种具有更高患者依从性和更好疼痛控制效果的新型控释骨架片提供了科学依据。